GlaxoSmithKline.
206 announcements.
206 announcements.
| Time | Date | Ticker | Company | Announcement |
|---|---|---|---|---|
| 07:00 | 22-11-2024 | GSK | GlaxoSmithKline | Japan approves first RSV vaccine for adults 50-59 |
| 15:30 | 19-11-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 19-11-2024 | GSK | GlaxoSmithKline | GLISTEN Trial of Linerixibat Meets Endpoint |
| 07:00 | 14-11-2024 | GSK | GlaxoSmithKline | GSK announces overall survival results for Blenrep |
| 15:00 | 13-11-2024 | GSK | GlaxoSmithKline | Block listing Interim Review |
| 15:30 | 12-11-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:01 | 11-11-2024 | GSK | GlaxoSmithKline | GSK publishes provisional 2025 dividend dates |
| 15:00 | 01-11-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 14:29 | 30-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 30-10-2024 | GSK | GlaxoSmithKline | 3rd Quarter Results |
| 07:00 | 24-10-2024 | GSK | GlaxoSmithKline | New positive Arexvy data in younger adults at risk |
| 15:30 | 17-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 16:09 | 16-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 16-10-2024 | GSK | GlaxoSmithKline | FDA accepts new drug application for gepotidacin |
| 15:30 | 14-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 14-10-2024 | GSK | GlaxoSmithKline | Positive results of ANCHOR trials of depemokimab |
| 15:33 | 11-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 10-10-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 17:48 | 09-10-2024 | GSK | GlaxoSmithKline | Zantac (ranitidine) litigation settlements |
| 11:45 | 08-10-2024 | GSK | GlaxoSmithKline | Positive efficacy data of Arexvy over 3 seasons |
| 15:00 | 01-10-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:30 | 24-09-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 24-09-2024 | GSK | GlaxoSmithKline | Positive EU opinion for GSK liquid Menveo vaccine |
| 13:20 | 18-09-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 17-09-2024 | GSK | GlaxoSmithKline | Japan Filing Acceptance: Blenrep Multiple Myeloma |
| 07:00 | 13-09-2024 | GSK | GlaxoSmithKline | China Breakthrough Therapy Designation for Blenrep |
| 15:30 | 12-09-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 12-09-2024 | GSK | GlaxoSmithKline | Positive mRNA flu vaccine Phase II headline data |
| 17:27 | 11-09-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 15:30 | 11-09-2024 | GSK | GlaxoSmithKline | Change of Registered Office |
| 07:00 | 11-09-2024 | GSK | GlaxoSmithKline | Update on phase I/II therapeutic HSV vaccine trial |
| 14:30 | 09-09-2024 | GSK | GlaxoSmithKline | Depemokimab late-breaking data presented at ERS |
| 15:30 | 06-09-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 06-09-2024 | GSK | GlaxoSmithKline | Positive Phase III results for Nucala in COPD |
| 15:00 | 02-09-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 29-08-2024 | GSK | GlaxoSmithKline | EMA approval on Arexvy for 50-59 at risk |
| 07:05 | 28-08-2024 | GSK | GlaxoSmithKline | Nucala approved in Japan for use in CRSwNP |
| 07:10 | 28-08-2024 | GSK | GlaxoSmithKline | SENKU Designation for Bepirovirsen in Japan |
| 07:00 | 28-08-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 15:30 | 21-08-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 20-08-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 20-08-2024 | GSK | GlaxoSmithKline | B7-H3 ADC US FDA Breakthrough Therapy Designation |
| 07:00 | 16-08-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 15:30 | 12-08-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 06-08-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 02-08-2024 | GSK | GlaxoSmithKline | FDA Expands Jemperli Approval |
| 15:00 | 01-08-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 31-07-2024 | GSK | GlaxoSmithKline | 2nd Quarter Results |
| 10:36 | 19-07-2024 | GSK | GlaxoSmithKline | Blenrep EMA Filing Acceptance |
| 15:30 | 18-07-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 16-07-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 15-07-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 12-07-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 03-07-2024 | GSK | GlaxoSmithKline | GSK and CureVac collaboration restructured |
| 15:00 | 01-07-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 17:37 | 28-06-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:05 | 24-06-2024 | GSK | GlaxoSmithKline | Omjjara approved in Japan for myelofibrosis |
| 07:00 | 24-06-2024 | GSK | GlaxoSmithKline | EMA validates Jemperli marketing authorisation |
| 15:30 | 21-06-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 12-06-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 11-06-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 10-06-2024 | GSK | GlaxoSmithKline | FDA approves Arexvy for adults 50-59 at risk |
| 15:00 | 03-06-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 13:03 | 03-06-2024 | GSK | GlaxoSmithKline | Unprecedented results in Jemperli trial continue |
| 07:05 | 03-06-2024 | GSK | GlaxoSmithKline | ASCO positive Blenrep DREAMM-8 trial results |
| 07:00 | 03-06-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 24-05-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 21-05-2024 | GSK | GlaxoSmithKline | Positive phase III asthma results for depemokimab |
| 07:00 | 17-05-2024 | GSK | GlaxoSmithKline | GSK completes sale of shares in Haleon plc |
| 16:42 | 16-05-2024 | GSK | GlaxoSmithKline | GSK announces intention to sell shares in Haleon |
| 15:30 | 14-05-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 13-05-2024 | GSK | GlaxoSmithKline | Block listing Interim Review |
| 16:57 | 08-05-2024 | GSK | GlaxoSmithKline | Board Committee Change |
| 15:30 | 03-05-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 01-05-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 01-05-2024 | GSK | GlaxoSmithKline | 1st Quarter Results |
| 07:00 | 24-04-2024 | GSK | GlaxoSmithKline | US FDA accepts new indication filing for Jemperli |
| 15:30 | 19-04-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 12:05 | 04-04-2024 | GSK | GlaxoSmithKline | Replacement - Total Voting Rights |
| 15:00 | 02-04-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:30 | 26-03-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 13:00 | 25-03-2024 | GSK | GlaxoSmithKline | Notice of AGM |
| 16:20 | 22-03-2024 | GSK | GlaxoSmithKline | Transfer of Treasury Shares |
| 15:36 | 22-03-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 09:30 | 18-03-2024 | GSK | GlaxoSmithKline | New Phase III Jemperli data in endometrial cancer |
| 15:48 | 13-03-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 17:12 | 08-03-2024 | GSK | GlaxoSmithKline | Board Committee Change |
| 07:00 | 07-03-2024 | GSK | GlaxoSmithKline | GSK announces positive Blenrep DREAMM-8 results |
| 16:00 | 06-03-2024 | GSK | GlaxoSmithKline | ViiV LAI vs oral SOC data in adherence-challenged |
| 15:00 | 01-03-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 12:15 | 01-03-2024 | GSK | GlaxoSmithKline | GSK publishes Annual Report 2023 |
| 07:05 | 29-02-2024 | GSK | GlaxoSmithKline | Directorate Change |
| 07:00 | 29-02-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 15:30 | 26-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 26-02-2024 | GSK | GlaxoSmithKline | GSK announces positive EAGLE-1 headline results |
| 15:30 | 22-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 21-02-2024 | GSK | GlaxoSmithKline | ViiV LAI superior to orals in adherence-challenged |
| 09:01 | 20-02-2024 | GSK | GlaxoSmithKline | Julie Brown - External Appointment |
| 15:30 | 19-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:32 | 15-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 15-02-2024 | GSK | GlaxoSmithKline | GSK completes acquisition of Aiolos Bio |
| 16:45 | 13-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding - Replacement |
| 15:40 | 13-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:35 | 13-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 13-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:05 | 06-02-2024 | GSK | GlaxoSmithKline | Shingrix 18+ at risk China filing review accepted |
| 07:10 | 06-02-2024 | GSK | GlaxoSmithKline | FDA accepts Arexvy filing for adults 50-59 at risk |
| 07:00 | 06-02-2024 | GSK | GlaxoSmithKline | GSK presents positive DREAMM-7 phase III data |
| 15:30 | 01-02-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 01-02-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 01-02-2024 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 31-01-2024 | GSK | GlaxoSmithKline | Final Results |
| 07:05 | 29-01-2024 | GSK | GlaxoSmithKline | EMA accepts Arexvy filing for adults 50-59 at risk |
| 07:00 | 29-01-2024 | GSK | GlaxoSmithKline | European Commission authorises Omjjara in the EU |
| 15:30 | 19-01-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 17:00 | 18-01-2024 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 15:30 | 17-01-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 17-01-2024 | GSK | GlaxoSmithKline | GSK completes sale of shares in Haleon plc |
| 16:40 | 16-01-2024 | GSK | GlaxoSmithKline | GSK announces intention to sell shares in Haleon |
| 15:30 | 16-01-2024 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 10-01-2024 | GSK | GlaxoSmithKline | Nucala approved in China for use in severe asthma |
| 07:00 | 09-01-2024 | GSK | GlaxoSmithKline | GSK enters agreement to acquire Aiolos Bio |
| 15:00 | 02-01-2024 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:30 | 21-12-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 16:44 | 20-12-2023 | GSK | GlaxoSmithKline | Publication of EMTN Suppl.Prospcts |
| 07:00 | 18-12-2023 | GSK | GlaxoSmithKline | Jemperli plus Zejula Trial Meets Endpoint |
| 15:30 | 13-12-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 12-12-2023 | GSK | GlaxoSmithKline | Japan accepts Arexvy filing for at risk adults |
| 07:00 | 11-12-2023 | GSK | GlaxoSmithKline | Jemperli plus chemotherapy EU authorisation |
| 15:02 | 04-12-2023 | GSK | GlaxoSmithKline | GSK publishes provisional 2024 dividend dates |
| 15:00 | 01-12-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 09:00 | 30-11-2023 | GSK | GlaxoSmithKline | Block Listing Application |
| 15:23 | 29-11-2023 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 07:00 | 27-11-2023 | GSK | GlaxoSmithKline | GSK announces positive DREAMM-7 headline results |
| 15:30 | 21-11-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 15-11-2023 | GSK | GlaxoSmithKline | Block listing Interim Review |
| 15:30 | 13-11-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 13-11-2023 | GSK | GlaxoSmithKline | GSK receives positive CHMP opinion for momelotinib |
| 15:00 | 01-11-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 01-11-2023 | GSK | GlaxoSmithKline | 3rd Quarter Results |
| 07:00 | 30-10-2023 | GSK | GlaxoSmithKline | Jemperli trial meets overall survival endpoint |
| 07:00 | 26-10-2023 | GSK | GlaxoSmithKline | NMPA approves Vocabria+Rekambys in China |
| 15:30 | 25-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 25-10-2023 | GSK | GlaxoSmithKline | New data for Arexvy, GSK’s RSV vaccine |
| 15:30 | 20-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 18-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 17-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 16-10-2023 | GSK | GlaxoSmithKline | Jemperli plus chemotherapy positive CHMP opinion |
| 15:30 | 13-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 12-10-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 11-10-2023 | GSK | GlaxoSmithKline | Zantac (ranitidine) litigation |
| 11:00 | 10-10-2023 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 07:00 | 09-10-2023 | GSK | GlaxoSmithKline | GSK and Zhifei announce vaccine partnership |
| 07:00 | 06-10-2023 | GSK | GlaxoSmithKline | GSK completes sale of shares in Haleon plc |
| 16:46 | 05-10-2023 | GSK | GlaxoSmithKline | GSK announces intention to sell shares in Haleon |
| 15:00 | 02-10-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:00 | 27-09-2023 | GSK | GlaxoSmithKline | Directorate Change |
| 07:00 | 25-09-2023 | GSK | GlaxoSmithKline | GSK RSV vaccine for older adults approved in Japan |
| 15:30 | 21-09-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 19-09-2023 | GSK | GlaxoSmithKline | Apretude for PrEP receives EMA approval |
| 07:00 | 18-09-2023 | GSK | GlaxoSmithKline | FDA approves Ojjaara (momelotinib) |
| 15:30 | 13-09-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 11-09-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 11-09-2023 | GSK | GlaxoSmithKline | Momelotinib filing accepted in Japan |
| 15:00 | 01-09-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 07:00 | 01-09-2023 | GSK | GlaxoSmithKline | GSK’s Nucala CRSwNP submission accepted in Japan |
| 15:14 | 31-08-2023 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 15:16 | 31-08-2023 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 15:30 | 25-08-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 22-08-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 10-08-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 09-08-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 13:05 | 08-08-2023 | GSK | GlaxoSmithKline | Publication of Base Prospectus |
| 15:30 | 28-07-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 26-07-2023 | GSK | GlaxoSmithKline | 2nd Quarter Results |
| 07:00 | 24-07-2023 | GSK | GlaxoSmithKline | Cabotegravir LA for PrEP receives positive CHMP |
| 15:30 | 20-07-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 17-07-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 13-07-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 03-07-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:43 | 28-06-2023 | GSK | GlaxoSmithKline | GSK completes acquisition of BELLUS Health |
| 07:00 | 27-06-2023 | GSK | GlaxoSmithKline | FDA Fast Track for Gonorrhoea Vaccine Candidate |
| 07:05 | 26-06-2023 | GSK | GlaxoSmithKline | Shingrix approved in Japan for adults 18 and over |
| 07:00 | 26-06-2023 | GSK | GlaxoSmithKline | GSK daprodustat gains positive EMA CHMP opinion |
| 15:30 | 23-06-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:33 | 23-06-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:37 | 23-06-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 23-06-2023 | GSK | GlaxoSmithKline | Statement: Zantac (ranitidine) litigation |
| 07:00 | 22-06-2023 | GSK | GlaxoSmithKline | GSK’s Arexvy recommended by ACIP |
| 07:00 | 21-06-2023 | GSK | GlaxoSmithKline | Season two data for GSK Arexvy RSV OA vaccine |
| 07:00 | 16-06-2023 | GSK | GlaxoSmithKline | Extension of FDA review period for momelotinib |
| 15:30 | 12-06-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 07:00 | 07-06-2023 | GSK | GlaxoSmithKline | EU authorisation of GSK’s RSV vaccine Arexvy |
| 07:00 | 06-06-2023 | GSK | GlaxoSmithKline | GSK receives US FDA file acceptance for Jemperli |
| 15:00 | 01-06-2023 | GSK | GlaxoSmithKline | Total Voting Rights |
| 15:30 | 22-05-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 14:00 | 16-05-2023 | GSK | GlaxoSmithKline | Holding(s) in Company |
| 15:30 | 15-05-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:00 | 15-05-2023 | GSK | GlaxoSmithKline | Block listing Interim Review |
| 15:30 | 12-05-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 09:50 | 12-05-2023 | GSK | GlaxoSmithKline | MenABCWY vaccine preliminary phase III results |
| 07:00 | 12-05-2023 | GSK | GlaxoSmithKline | GSK completes sale of shares in Haleon plc |
| 07:05 | 12-05-2023 | GSK | GlaxoSmithKline | Statement: Zantac Litigation Update BC Canada |
| 16:41 | 11-05-2023 | GSK | GlaxoSmithKline | GSK announces intention to sell shares in Haleon |
| 15:30 | 09-05-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |
| 15:30 | 04-05-2023 | GSK | GlaxoSmithKline | Director/PDMR Shareholding |